Associated Papers
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.
Alvarez K et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2017
KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
Zhou L et al.
Medical Oncology (northwood, London, England), 2016
Select a paper to view details